Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2025)
Aurora Cannabis (ACB) reported Net Income towards Common Stockholders of $2.0 million for Q4 2025, down 90.23% year-over-year from $20.4 million in Q4 2024, and up 105.3% quarter-over-quarter from -$37.5 million in Q3 2025.
Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has 9 years of Net Income towards Common Stockholders data on file, last reported at $2.0 million in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at $2.0 million, down 90.23% year-over-year; the trailing twelve-month figure through Dec 2025 was -$60.3 million (down 782.95% YoY), and the FY2025 annual result was $11.5 million, up 128.94% from the prior year.
- Net Income towards Common Stockholders advanced to $2.0 million in Q4 2025 per ACB's latest filing, from -$37.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $20.4 million in Q4 2024 and troughed at -$799.1 million in Q1 2022.
- A 5-year average of -$96.4 million and a median of -$15.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 212.54% in 2024, then plunged 707.94% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$60.2 million in 2021, then gained by 16.95% to -$50.0 million in 2022, then surged by 63.81% to -$18.1 million in 2023, then surged by 212.54% to $20.4 million in 2024, then plunged by 90.23% to $2.0 million in 2025.
- Business Quant data shows ACB's Net Income towards Common Stockholders at $2.0 million in Q4 2025, -$37.5 million in Q3 2025, and -$11.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | -37.49 Mn |
| Jun 30, 2025 | -11.47 Mn |
| Mar 31, 2025 | -13.36 Mn |
| Dec 31, 2024 | 20.36 Mn |
| Sep 30, 2024 | -13.39 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | -1.65 Mn |
| Dec 31, 2023 | -18.09 Mn |
| Sep 30, 2023 | -1.91 Mn |
| Dec 31, 2022 | -49.98 Mn |
| Sep 30, 2022 | -37.59 Mn |
| Jun 30, 2022 | -488.98 Mn |
| Mar 31, 2022 | -799.09 Mn |
| Dec 31, 2021 | -60.19 Mn |
| Sep 30, 2021 | -9.40 Mn |
| Jun 30, 2021 | -87.26 Mn |
| Mar 31, 2021 | -130.67 Mn |
| Dec 31, 2020 | -231.45 Mn |
| Sep 30, 2020 | -88.27 Mn |